Vanguard Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$88.1B Buy
81,965,974
+1,006,885
+1% +$963M 1.28% 10
2025
Q3
$61.8B Buy
80,959,089
+551,659
+0.7% +$411M 0.92% 12
2025
Q2
$62.7B Buy
80,407,430
+1,183,038
+1% +$919M 1.01% 12
2025
Q1
$65.4B Buy
79,224,392
+4,975,395
+7% +$4.14B 1.18% 10
2024
Q4
$57.3B Buy
74,248,997
+475,530
+0.6% +$394M 1% 12
2024
Q3
$65.4B Sell
73,773,467
-85,541
-0.1% -$76.9M 1.17% 10
2024
Q2
$66.9B Buy
73,859,008
+1,113,997
+2% +$891M 1.28% 9
2024
Q1
$56.6B Buy
72,745,011
+1,133,810
+2% +$807M 1.12% 10
2023
Q4
$41.7B Buy
71,611,201
+1,035,599
+1% +$604M 0.91% 13
2023
Q3
$37.9B Buy
70,575,602
+659,838
+0.9% +$340M 0.93% 13
2023
Q2
$32.8B Sell
69,915,764
-81,618
-0.1% -$34.2M 0.78% 17
2023
Q1
$24B Sell
69,997,382
-3,432,481
-5% -$1.16B 0.61% 22
2022
Q4
$26.9B Buy
73,429,863
+841,546
+1% +$298M 0.73% 17
2022
Q3
$23.5B Buy
72,588,317
+996,990
+1% +$316M 0.69% 17
2022
Q2
$23.2B Buy
71,591,327
+1,110,149
+2% +$333M 0.65% 21
2022
Q1
$20.2B Buy
70,481,178
+1,219,424
+2% +$314M 0.48% 27
2021
Q4
$19.1B Buy
69,261,754
+218,594
+0.3% +$55.4M 0.43% 35
2021
Q3
$16B Buy
69,043,160
+73,612
+0.1% +$18.2M 0.4% 39
2021
Q2
$15.8B Sell
68,969,548
-317,415
-0.5% -$63.8M 0.39% 41
2021
Q1
$12.9B Buy
69,286,963
+625,469
+0.9% +$122M 0.35% 48
2020
Q4
$11.6B Sell
68,661,494
-503,870
-0.7% -$75.2M 0.34% 51
2020
Q3
$10.2B Sell
69,165,364
-2,439,723
-3% -$378M 0.34% 56
2020
Q2
$11.8B Sell
71,605,087
-1,070,561
-1% -$164M 0.42% 41
2020
Q1
$10.1B Buy
72,675,648
+1,755,598
+2% +$241M 0.43% 40
2019
Q4
$9.32B Sell
70,920,050
-45,200
-0.1% -$5.24M 0.32% 58
2019
Q3
$7.94B Sell
70,965,250
-169,128
-0.2% -$18.8M 0.29% 61
2019
Q2
$7.88B Buy
71,134,378
+578,045
+0.8% +$68.1M 0.3% 57
2019
Q1
$9.16B Sell
70,556,333
-5,101,886
-7% -$620M 0.36% 48
2018
Q4
$8.76B Buy
75,658,219
+1,525,234
+2% +$170M 0.39% 41
2018
Q3
$7.96B Buy
74,132,985
+511,752
+0.7% +$51.2M 0.31% 57
2018
Q2
$6.28B Buy
73,621,233
+585,843
+0.8% +$48.1M 0.26% 66
2018
Q1
$5.65B Buy
73,035,390
+812,993
+1% +$65.4M 0.25% 69
2017
Q4
$6.1B Buy
72,222,397
+917,021
+1% +$78M 0.27% 61
2017
Q3
$6.1B Buy
71,305,376
+1,097,485
+2% +$90M 0.29% 58
2017
Q2
$5.78B Buy
70,207,891
+1,610,885
+2% +$131M 0.28% 58
2017
Q1
$5.77B Buy
68,597,006
+2,181,701
+3% +$175M 0.3% 54
2016
Q4
$4.88B Buy
66,415,305
+1,470,123
+2% +$109M 0.27% 61
2016
Q3
$5.21B Buy
64,945,182
+1,708,505
+3% +$137M 0.31% 52
2016
Q2
$4.98B Buy
63,236,677
+1,350,329
+2% +$102M 0.31% 53
2016
Q1
$4.46B Buy
61,886,348
+1,973,169
+3% +$149M 0.29% 60
2015
Q4
$5.05B Buy
59,913,179
+1,552,428
+3% +$129M 0.34% 51
2015
Q3
$4.88B Buy
58,360,751
+892,283
+2% +$75.3M 0.35% 50
2015
Q2
$4.8B Buy
57,468,468
+697,084
+1% +$53.1M 0.32% 51
2015
Q1
$4.12B Buy
56,771,384
+2,042,825
+4% +$145M 0.28% 61
2014
Q4
$3.78B Buy
54,728,559
+1,731,599
+3% +$117M 0.27% 65
2014
Q3
$3.44B Buy
52,996,960
+1,036,766
+2% +$65.6M 0.27% 64
2014
Q2
$3.23B Buy
51,960,194
+778,619
+2% +$46.5M 0.25% 67
2014
Q1
$3.01B Buy
51,181,575
+1,056,459
+2% +$59M 0.25% 71
2013
Q4
$2.56B Buy
50,125,116
+719,465
+1% +$36M 0.22% 81
2013
Q3
$2.49B Buy
49,405,651
+1,065,947
+2% +$55.8M 0.24% 77
2013
Q2
$2.37B Buy
+48,339,704
New +$2.63B 0.25% 71

Other funds holding LLY

Vanguard Group's LLY Position: Q4 2025 in Review

Vanguard Group increased its Eli Lilly (LLY) stake by 1.2% in Q4 2025, buying an estimated $963M and bringing the position to 81,965,974 shares worth $88.1B. The position accounts for 1.28% of the portfolio, ranked #10.

Vanguard Group first reported a position in LLY in Q2 2013 and has held it in 51 quarters since. 4,428 funds tracked by Wall St. Rank hold LLY as of Q4 2025.

  • Vanguard Group held 81,965,974 shares of Eli Lilly worth $88.1B as of Q4 2025.
  • Vanguard Group bought 1,006,885 Eli Lilly shares in Q4 2025, an estimated $963M.
  • Eli Lilly made up 1.28% of Vanguard Group's portfolio in Q4 2025, its #10 holding.
  • Vanguard Group first reported a position in Eli Lilly in Q2 2013 and has held it in 51 quarters since.
  • 4,428 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.